

ANNUAL REPORT 2022

CURE OUR OVARIAN CANCER
CHARITABLE TRUST

For the Year Ended
31st March 2022





HELPING WOMEN
LIVE BETTER,
LONGER LIVES

CONTENTS

04	ENTITY INFORMATION
08	OUR TRUSTEES
10	FOUNDING TRUSTEES REPORT
11	ABOUT CURE OUR OVARIAN CANCER
14	APPROVAL OF FINANCIAL REPORT
15	STATEMENT OF SERVICE PERFORMANCE NEW ZEALAND
16	MIRACLE’S STORY
21	STATEMENT OF SERVICE PERFORMANCE WORLDWIDE
22	HONOURING JESS’S CONTRIBUTION
28	STATEMENT OF FINANCIAL PERFORMANCE
29	STATEMENT OF FINANCIAL POSITION
30	STATEMENT OF CASH FLOWS
31	STATEMENT OF ACCOUNTING POLICIES
32	NOTES TO THE PERFORMANCE REPORT

ENTITY INFORMATION

NAME OF THE ENTITY

14/11/2018 Cure My Ovarian Cancer (Low Grade Serous) Charitable Trust
05/12/2018 Cure Our Ovarian Cancer (Low Grade Serous) Charitable Trust
Also known as: Cure Our Ovarian Cancer, Cure Our Ovarian Cancer NZ and Ovarian Cancer New Zealand.

- A note on terms used:
- Unless otherwise specified, “ovarian cancer” can be taken to include cancer of the fallopian tubes, peritoneum and ovaries.
 - Low-grade serous ovarian cancer may also be referred to in this report as low-grade serous carcinoma or cancer, LGSOC and LGSC.
 - Cure Our Ovarian Cancer may be referred to as COOC

TYPE OF ENTITY AND LEGAL BASIS

Cure Our Ovarian Cancer was registered as a Charitable Trust under the New Zealand Charitable Trusts Act 1957, on June 2018; and with the Department of Internal Affairs Services as a Charity on the 31st of July 2018.

REGISTRATION DETAILS

Charitable Trusts Act Registration Number 2707031
DIA Charities Services Registration Number CC55925
Registration Date: 31/07/2018

OUR MISSION

- To reduce deaths, extend lives and empower people living with ovarian cancer.
- Within New Zealand we focus on all wāhine with ovarian cancer.
- Globally we focus on a poorly survivable younger women’s ovarian cancer call low-grade serous carcinoma.

ENTITY STRUCTURE

The Trust operates from Dunedin. The Trust Deed states that there must be between two and five trustees. The Trust currently has four trustees that constitute the governance board. The existing Trustees have power to appoint further Trustees from members of the public who have an interest in the Trust’s charitable purpose. On the 2nd of August 2019 by Deed of Variation of Trust, a separate New Zealand Purposes Fund was created. On the 11th of October 2019 the trustees removed donee status from The Trust to avoid limits on overseas disbursement of donations from outside of New Zealand. The New Zealand Purposes Fund retains donee status.

Present members of the governing body are:

Jane Ludemann (Founder / Trustee)
Alicia Didsbury (Trustee)
Alana Allan (Trustee)
Liz Pennington (Trustee)

MAIN SOURCES OF CASH AND RESOURCES

Cure Our Ovarian Cancer’s primary source of funding is primarily through donations and fundraisers by the general public. We also received donations and fundraising proceeds through businesses, and community organisations including this year: Rural Women New Zealand, Rotary Oamaru, Temuka District Lions Club, Taumarunui Cosmopolitan Club, Inner Wheel Club of Plimmerton Tongs, Te Awamutu Sports Senior Rugby, Waiaireka Valley Lions Club, Soroptomist International of Wellington and Altrusa International. Additionally this year we received two grants, at the end of the financial period to help with ovarian cancer support services (GSK) and charity administration (Lottery Grant).

VOLUNTEERS

Our governing body is made up of volunteers, and all our activities are undertaken by volunteers. No trustee receives remuneration or a fee.

In addition to our trustees, we gratefully acknowledge the assistance of:

Anne Reddington	Libertine Teas
William Munn	Coffee Supreme
Gavin McLelland	New Zealand Lottery Grants Board
Diane Evans-Wood	GSK
Katie Wilkins	Auckland University Accelerate Program
Daniella Paolozzi	Rachel Wilson and Lisa Finucane of the NZ Ovarian Cancer Support Group
Elizabeth Miller	Nicole Andrews and the Board of STAAR Ovarian cancer
Leslie Vreeland-Corpe	The UK LGSOC Patient Group
Brianna Wagner	Living With Ovarian Cancer PodCast
Lexi Mestas	Tash Crosby of Talk Peach Gynaecological Foundation
Cecile Hryhorczuk	Graci - the Gynaecological Cancer Research Trust
Alex Coppock-Bunce	The BC Cancer Foundation
Elsa Larsen	ANZGOG
Kari Neumeyer	The University of Edinburgh
Harvey Green Wyatt Chartered Accountants	Rural Women New Zealand
Topham Guerin Creative Agency	Soroptomists New Zealand
Go Media	Associate Professor Peter Sykes
Landsec	Dr Kate Gregory
JC Decaux UK	Our Ovarian Cancer Communities
DP Marketing Communications Northampton	
Tea Total	
Astrazeneca	
William Munn	

ENTITY INFORMATION

CONTACT

Email

office@cureourovariancancer.org

NEW ZEALAND

Website

CureOurOvarianCancer.org/nz
ovariancancer.org.nz

Facebook

facebook.com/ovariancancernz

Instagram

instagram.com/ovariancancernz

Postal Address

PO Box 143, Dunedin Central,
Dunedin 9054, New Zealand

WORLDWIDE (LOW-GRADE SEROUS CANCER)

Website

CureOurOvarianCancer.org

Facebook

facebook.com/CureOurOvarianCancer


Instagram

instagram.com/cureourovariancancer

Twitter

Twitter.com/Cure_Ovarian_Ca

THE WOMEN IN
OUR COMMUNITY
CONTINUALLY INSPIRE
US TO DO BETTER



OUR TRUSTEES



Jane Ludemann

BSc BOptom (Hons)

Jane was diagnosed with low-grade serous carcinoma in 2017 at the age of 32.

Based in Otago, Jane is an experienced therapeutically qualified optometrist who has worked in all over New Zealand; and in Canada, in private practice and within hospital ophthalmology departments. In 2019 she retired to devote more time to Cure Our Ovarian Cancer.

Jane is an accomplished public speaker and has long been interested in research, global problems and science education. Before pursuing optometry at Auckland University she completed a science degree at Otago University and was awarded a Summer Research Scholarship at AgResearch. She represented Otago University at the World Debating Competitions in Singapore. She was a participant in the THIMUN Youth Assembly (an international youth conference in the Netherlands) and an active volunteer for UN Youth New Zealand. In addition she was a five time Student Helper at Otago University Hands on Science - a week long camp designed to get young people enthusiastic about science.

On graduation, Jane gave back to the community as a volunteer for Land Search and Rescue in addition to voluntary optometry aid work overseas. She was part way through a Masters of Professional Accounting and Finance when she was diagnosed.

Since her cancer diagnosis she has completed university study in cancer biology, advanced immunology and integrated digital marketing, in addition to reading every ovarian cancer research paper she can find.

Jane runs all of the day to day operations of Cure Our Ovarian Cancer, including the website and social media - and has co-authored articles on ovarian cancer for the Gynecological Oncology Journal and NZ Doctor Magazine. In 2022 she was invited to speak at the Society of Gynecologic Meeting, one of the largest gatherings of gynaecological cancer specialists in the world.



Liz Pennington

Liz brings an extensive range of skills through her leadership experience in the not for profit sector and experience as a Registered Nurse, management consultant working in mental health and wellbeing, and work with communities experiencing psychological trauma.

Liz was motivated to join Cure Our Ovarian Cancer after hearing Jane do an "amazing" presentation at parliament. She has a heart for ovarian cancer because of the personal experiences of her good friend, the late Gaylene Kepka. Gaylene inspired Liz to make change for good.

Liz is particularly passionate about consumer designed services and ensuring that the ovarian cancer community feel listened to and have a strong voice. She has been instrumental in the development of Cure Our Ovarian Cancer's support meetings.

Liz is originally from Hawkes Bay and lives at Lake Rotoma in the Bay of Plenty and is a devoted nan to her three granddaughters.



Alana Allan

Alana is an operations leader in the legal sector, with experience across change management, technology, strategy, organisational performance and financial services.

Based in Christchurch she is passionate about contributing to society, with a special emphasis on not for profit governance. She has held a number of board positions including roles with the RSA, Pregnancy Help, CAANZ and Dunedin Budget Advisory.

Alana was motivated to join Cure Our Ovarian Cancer after attending a powerful talk by Jane Ludemann in Dunedin. Alana's vision for COOC is to see greater awareness & support of ovarian cancer rise whilst helping grow COOC's reach in the advocacy and research space.



Alicia Didsbury

Alicia has been working on cancer immunotherapy at Auckland University for over 12 years. Her first exposure to ovarian cancer was following the diagnosis of a family member. She was shocked to discover the relative lack of research internationally, and clinical trials locally for such a common cause of cancer death.

This led to a career pivot into ovarian cancer research and ignited a desire to address the systemic inequities faced by ovarian cancer patients.

Alicia is particularly passionate about making ovarian cancer an attractive field for New Zealand researchers and believes there are significant opportunities for New Zealand researchers to do more, to impact survival on the global stage.

OUT-GOING TRUSTEE



Elspeth Ludemann

BA, Dip Journ

Cure Our Ovarian Cancer would like to acknowledge the support and assistance of Elspeth Ludemann who in 2021 stepped back from the trustee role. Elspeth continues to contribute to Cure Our Ovarian Cancer as a volunteer and we would like to thank her for her service to the ovarian cancer community.

FOUNDING TRUSTEE'S REPORT



JANE LUDEMANN



When I was diagnosed with low-grade serous ovarian cancer in 2017, I was told I likely had five to fifteen years left to live. As a consequence of this knowledge, sustainability, contingency plans and succession have been necessary considerations that have formed part of our organisational vernacular from day one.

Many other charity founders have told me that being both cancer patient and charity founder is a less than ideal situation. It requires a lot of time which is both a limited and immensely valuable asset in this context, and personal sacrifice. But while it may be less than ideal, I can't envisage going back and making a different choice. Cure Our Ovarian Cancer was founded very much out of necessity. When faced with a huge unmet need, that no other organisation was addressing within New Zealand, nor indeed the world - I was faced with a realisation that sometimes if you want to see change, you have to be that change.

And so in that context, it has been both a privilege and a pleasure to reach a point in the organisation's development where my health is not the limiting capacity. Indeed, I am fortunate that after five years, my cancer treatment continues to work. Something I am especially grateful for knowing first hand that this has not been the case for so many other women in my situation. Including Jessica Becraft, a young mother in her thirties who passed away in 2021, just a year after founding our American sister charity STAAR Ovarian Cancer. Jessica's loss is another tragic example of how ovarian cancer destroys the lives of many women, but the legacy she leaves is STAAR Ovarian Cancer which has continued to grow and strengthen since her passing.

While funding was, and remains the most significant limiting factor to the impact Cure Our Ovarian Cancer can make as an organisation, in 2021 it became apparent that our overall organisational capacity i.e. hands on the ground, also needed to increase. We took steps to recruit additional trustees and could not have asked for better applicants. Our new trustees are immensely accomplished in their own right and bring important skill sets and strengths to our organisation - not least their passion for improving outcomes for people with ovarian cancer. In addition their appointment helped relieve our immediate capacity concerns.

This reporting period has been a lot about consolidation and strengthening. As you'll see from our report we deepened our efforts within New Zealand while continuing to support and fund research for the low-grade serous cancer community. A lot of our achievements this year required time and included longer-term development and planning. As a consequence expenditure was lower than previous years, but we will more than make up for this in the next reporting period.

In addition, during this reporting period we discontinued our acceptance of international donations, directing people instead to our international partner research organisations. This led to reduced overall revenue in the accounts but as these international funds were always on-directed to partner organisations the net result for Cure Our Ovarian Cancer has been the same outcome with less administration and a simpler charity tax structure.

In full transparency, even with our increased capacity this year, we find ourselves in a Catch-22 situation. To further address the significant unmet needs of the ovarian cancer community, we need paid assistance but it is hard to justify this expenditure with our current donation level. Our board remains confident that the generous New Zealand community will respond to this need, and in the meantime we have received a \$25,000 grant from the New Zealand Lottery Grants Board which will allow us to appoint a part-time administrator.

To end this summary with a few highlights - we were one of just a few organisations world-wide to receive a 2021 World Ovarian Cancer Coalition Impact Award and shortlisted for the NZ Charity Reporting Awards. Our "An Ad You Can't Miss For A Cancer You Do" campaign featured on over 350 billboards across New Zealand, the UK and US (completely donated). We made substantial inroads to the development of a New Zealand support program and as always, managed to fund some very worthwhile and needed research to improve women's survival.

In the context of a very difficult cancer, it was a good year.

Jane Ludemann

Founding Trustee of Cure Our Ovarian Cancer

ABOUT CURE OUR OVARIAN CANCER

Cure Our Ovarian Cancer exists to reduce deaths, extend lives and empower people living with ovarian cancer.

We are the only ovarian cancer organisation in New Zealand and focus on improving outcomes for all wāhine with ovarian cancer.

We also work globally to improve outcomes for a poorly survivable younger women's ovarian cancer called low-grade serous carcinoma - for the benefit of New Zealanders and women around the world.

HOW WE DO THIS:

NEW ZEALAND

In New Zealand we work to improving the lives of ALL wāhine with a diagnosis of ovarian cancer through:

Education - earlier diagnosis

Cure Our Ovarian Cancer provides ovarian cancer education and symptoms resources to the general public and health professionals with the purpose of reducing the time taken for New Zealanders to be diagnosed with ovarian cancer.

Advocacy - a national voice

Cure Our Ovarian Cancer undertakes consultation with affected women and stakeholder groups including medical professionals, and advocates for evidence based changes in our health system and government to improve the diagnosis, treatment, survival and support available for people living with ovarian cancer.

Support - empowering people throughout their diagnosis

Cure Our Ovarian Cancer provides information and support to people diagnosed with ovarian cancer to help people make informed decisions about their health and make what can be a really tough and isolating diagnosis, that bit easier.

Research - improving survival

Research is the most important area of our work. Cure Our Ovarian Cancer funds research directly, and works to improve the quality and quantity of research within New Zealand to improve the survival of our least survivable women's cancer.

HOW WE DO THIS:

WORLDWIDE

Globally we work to improve the survival of women with a difficult to treat, younger women's cancer called low-grade serous - for the benefit of New Zealanders and women around the world.

We were the first organisation in the world dedicated to low-grade serous ovarian cancer, and this continues to be the primary focus of our work overseas. Though it is "rare" we estimate that there are over 40,000 women living with low-grade serous cancer world-wide.

Support - empowering people throughout their diagnosis

Cure Our Ovarian Cancer provides information and support for people living with low-grade serous ovarian cancer through our website and a peer support women-led Facebook group. As a rare ovarian cancer, many people struggle to find good information and receive evidence based care due to its rarity. We help connect them to each other, to provide support and through our website offer medically reviewed information to guide them through their treatment.

Research - improving survival

Ovarian cancer is under-researched, but rare ovarian cancers like low-grade serous are severely so. We help drive change by empowering women affected and their communities to fundraise and support researchers in their country working directly to improve their survival. We have a particular focus in Australia, Canada, the United Kingdom and the United States of America.

IMPACT AWARD



Cure Our Ovarian Cancer was honoured to be a recipient of the inaugural 2021 Impact Awards by the World Ovarian Cancer Coalition.

We received the award in recognition of our World Ovarian Cancer Day campaign which was organised by women with low-grade serous ovarian cancer and featured women with ovarian cancer from New Zealand, Canada, the United Kingdom, India, Australia, Austria and America on over 350 billboards, with news coverage in 3 countries including TVNZ in New Zealand, The Independent in the United Kingdom and CTV News in Canada.

The campaign was entirely donated thanks to the support of Topham Guerin, DP Marketing and Communications and generous billboard companies. "An Ad You Can't Miss For A Cancer You Do" was designed to draw attention to the lack of symptoms awareness and difficulty receiving a diagnosis and lack of resourcing in ovarian cancer. Internationally we used this to highlight symptoms in younger women and the need for investment into low-grade serous cancer research. Within New Zealand we used the campaign to highlight symptoms awareness and the lack of government funding and resourcing.

OVARIAN CANCER IN NEW ZEALAND

OVARIAN CANCER
KILLS MORE
WOMEN
THAN THE
ROAD TOLL,
SUICIDE &
MELANOMA

90%
OF KIWIS CAN'T
NAME A SINGLE
SYMPTOM

ON AVERAGE
WOMEN WITH
OVARIAN CANCER
HAVE TO VISIT
THEIR DOCTOR
3-5 TIMES
BEFORE BEING
TESTED

MOST YEARS THE
GOVERNMENT
DOESN'T FUND
ANY OVARIAN
CANCER RESEARCH

LOW-GRADE SEROUS CARCINOMA

LOW-GRADE
SEROUS CARCINOMA
IS THE
4TH
MOST COMMON
OVARIAN CANCER

IT DISPROPORTIONATELY
AFFECTS
YOUNGER
WOMEN

WITH CURRENT
TREATMENTS
MANY WOMEN'S
CANCER
WILL RETURN


THE MEDIAN
SURVIVAL IS
10 YEARS

APPROVAL OF FINANCIAL REPORT

Cure Our Ovarian Cancer Charitable Trust For the year ended 31 March 2022


The Trustees are pleased to present the approved financial report including the historical financial statements of Cure Our Ovarian Cancer (Low Grade Serous) Charitable Trust for year ended 31 March 2022.

APPROVED




Jane Ludemann
Trustee

Date: 15/10/22



Alana Murray
Trustee

Date: 15/10/22



Alicia Didsbury
Trustee

Date: 15/10/22



Elizabeth Pennington
Trustee

Date: 15/10/22

STATEMENT OF SERVICE PERFORMANCE NEW ZEALAND

MIRACLE'S STORY

Miracle Marsh of Whakatane, New Zealand, was diagnosed with mucinous ovarian carcinoma at the start of 2022 at the age of 27.



“As a young working mama, I never thought cancer would be part of my journey.”



Miracle has documented her experience with ovarian cancer on Facebook and Instagram through her page [@the.only.reminder](#)

One-third of Māori and Pacific wāhine with ovarian cancer are diagnosed under the age of 45 years old.

Miracle had been experiencing increased urgency to urinate, pain in her lower abdomen and pelvis, fatigue, change in bowel habits, loss of appetite and breathlessness.

“I also had swelling of the abdomen to the point where I looked ready to give birth.” After a negative pregnancy test, she was referred for a number of scans.

“My GP’s first thought was not ovarian cancer but liver cirrhosis,” Miracle said. “These results were slow and I chased my GP for answers and phoned almost every day to talk about my symptoms and my mental/emotional state, which was deteriorating.”

Eventually, she learned that she had a large mass and fluid in the abdomen that could be ovarian cancer. She was referred to a gynaecologist who requested additional tests, but then incorrectly told Miracle that the results were negative.

“Being misdiagnosed was the most traumatic part of this journey as I was told by my gynaecologist that pathology came back with no findings from the first biopsy and I was cleared for cancer,” she said.

After learning that cancer cells had in fact been found, Miracle had a laparotomy that removed her right ovary and fallopian tube along with a biopsy of the omentum and 6 litres of ascites fluid. She finally received an official diagnosis of stage 1C3 mucinous ovarian carcinoma.

She had another surgery to remove her other ovary and fallopian tube, uterus and appendix, and is currently undergoing chemotherapy.

Though Miracle’s cancer was diagnosed relatively early, there is still uncertainty. Stage 1C3 means cancer cells were detected in fluid taken during surgery from her abdomen and pelvis.

“My surgeon told me that chemotherapy isn’t always effective in my type of ovarian cancer. That’s hard to hear. Will I get to see my tamariki grow up? I really hope so,” she said. “I believe and know I should have been diagnosed a lot sooner, and I know I’m not the only one this has happened to.

“My hope is to bring awareness to my whanau and your whanau by sharing this journey,” she said. “Many voices create an impact and all wāhine deserve a fighting chance. We need to make ovarian cancer diagnosis easier.”

ENCOURAGING EARLIER DIAGNOSIS THROUGH EDUCATION AND AWARENESS:

PUBLIC EDUCATION:

- Field Days with Rural Women. Over 130,000 people attended Mystery Creek Field Days. Rural Women New Zealand made ovarian cancer a focus of their stall and helped us educate attendees, distributing symptoms cards and posters.
- Social Media Post Views: Symptoms education is a huge part of our social media content. In New Zealand 199,745 people viewed our Facebook content with a further 57,776 people who viewed our Instagram content across the year.
- Increased visibility on external sites: Cure Our Ovarian Cancer helped the newly formed Te Aho o Te Kahu, Cancer Control Agency, develop their ovarian cancer information page on their website.
- National Billboard campaign: With the generous support of Go Media and Topham and Guerin, Cure Our Ovarian Cancer ran billboards across the country on 47 billboards across 13 main centres of New Zealand. The campaign featured New Zealander’s alongside the tagline “An Ad You Can’t Miss. For A Cancer You Do. It was designed to highlight, the need for individuals to be educated on the symptoms of ovarian cancer, and a reminder to society and the government that ovarian cancer is both the deadliest women’s cancer, and one of our least funded.



FIELD DAYS RURAL WOMEN NEW ZEALAND



NATIONAL BILLBOARD CAMPAIGN NEW ZEALAND

HEALTH PROFESSIONAL EDUCATION:

- GP Review: Cure Our Ovarian Cancer co-authored an Ovarian Cancer Review with Associate Professor Peter Sykes - to educate GPs on its diagnosis, which was published in the popular GP publication NZ Doctor Magazine in February.
- Survivors Teaching Students: Cure Our Ovarian Cancer supported ANZGOG with the launch of their important Survivors Teaching Students (STS) Program. STS brings women with ovarian and other gynaecological cancers together with medical students and young doctors to share their experience and deliver important education relating to the diagnosis of ovarian cancer. The goal is to equip future and current health professionals with the skills they need to recognise and diagnose ovarian cancer. Founder Jane Ludemann participated in the first New Zealand session, and facilitated the second session.
- Good Diagnosis Awards: Cure Our Ovarian Cancer called for nominations from the ovarian cancer community for health professionals who provided prompt assistance at some point in their journey to aid their diagnosis. Recipients were provided with a literature review, ovarian cancer symptoms posters and our top ten tips for diagnosis and encouraged to sit down with their colleagues over a cuppa to share their learnings. Thanks to Tea Total, Libertine Tea and Coffee Supreme who kindly donated their delicious products for this purpose.
- COOC Developed a health professional “Hub” on our website which includes links to our diagnosis resources, literature reviews, continuing education courses and the UK and Australian diagnosis guidelines (NZ currently lacks our own national guidelines).

The Ovarian Cancer New Zealand Support Group was founded by Rachel Wilson. She became involved with ovarian cancer support and advocacy after she and her sister lost her mother Leonie Coates in 2006. Rachel is one of New Zealand's longest standing volunteers in the ovarian cancer space.

- Cure Our Ovarian Cancer continued to assist in the administration of the Ovarian Cancer New Zealand Support Group on Facebook supporting 248 members with ovarian cancer in 2021.
- Support Group Development: Cure Our Ovarian Cancer identified a need in the ovarian cancer community for face to face connection. In 2021 we hosted a pilot zoom peer support session. The feedback was overwhelmingly positive with some participants noting that it was the first time they had ever spoken to someone else with their cancer. During 2021/22 we undertook consultation with the ovarian cancer community, secured pilot funding through a grant from GSK and worked with a volunteer psychology intern (William Munn) to develop the program. At the end of this reporting period COOC was recruiting for a counsellor to facilitate the group.
- Written information: We added 9 new information resources on website including: a guide to leaving memories for children, sex and ovarian cancer; and sub-type specific diagnosis guides for high-grade serous and clear-cell ovarian cancer.

ADVOCACY | GIVING OVARIAN CANCER A NATIONAL VOICE

- Visibility within government. When we don't talk about an issue, it's easy to make the assumption that it isn't important. Until recently ovarian cancer was absent from the Ministry of Health consumer health education - despite the inclusion of other less deadly cancers. It took concerted campaigning, for over a year, but we finally got ovarian cancer added to The Ministry of Health website! <https://www.health.govt.nz/your-health/conditions-and-treatments/diseases-and-illnesses/ovarian-cancer>
- New professional resources for ovarian cancer. After engagement with Cure Our Ovarian Cancer, Te Aho o Te Kahu commissioned BPAC NZ to publish a series on ovarian cancer, and other gynaecological cancers. Development of the series is on-going. <https://bpac.org.nz/bulletin/bestpractice/forty-four.aspx>
- 5 Government submissions - on issues of importance to ovarian cancer, including: two national reviews - on Pharmac (the national drug funding agency), and the Pay Ora Healthy Futures Bill (the national health system), and 3 submissions to Pharmac on pharmaceutical funding including Olaparib (whose funding was extended), Niraparib in conjunction with Talk Peach Gynaecological Foundation (currently under assessment) and bevacizumab/Avastin (instead of declining the application our submission helped convince Pharmac to seek further clinical advice. This was really positive as 84 other diseases had their medicines declined as part of the review, though we do note that the application to fund Avastin was first made in 2013).
- On-going consultation relating to our 2021 Petition Presentation with women, GPs, cancer specialists, radiology and sonography. As part of this we spoke at the NZ Gynaecological Cancer Group Medical Conference and submitted multiple official information act requests to District Health Boards.

Our Official Information Act Requests showed that there are significant barriers to accessing ovarian cancer testing in New Zealand with many areas exhibiting low rates of CA-125 blood testing. In addition many women with ovarian cancer symptoms are facing waits of months for an ultrasound to be diagnosed, and in some instances referrals are being declined outright

RESEARCH



Our 2021 Cure Our Ovarian Cancer grant recipient was Dr Kenny Chitcholtan, for the project entitled:

Using proteomic phosphopeptides to predict the efficacy of drug combination in a trametinib-resistant low-grade ovarian cancer in 3D cell model.

Special mention to the Graci Foundation, who kindly administered our grants process alongside their gynaecological cancer research grants.

"A huge thank you to Cure Our Ovarian Cancer and researchers for trying to find what must feel like the needle in the haystack sometimes or often.

There are so many reasons why your work is important but to me it would be to prevent another child looking at its mother telling them they have cancer. We always have been open about my cancer (DX March 2020) but my 6 year old only just now has an understanding of what it means and it put such fear into his little eyes. Heartbreaking for any parent to watch and hopefully with your valuable work this fear will be replaced with laughter and smiles.

Don't give up, neither will we, you can do this."

- Lin, low-grade serous ovarian cancer, New Zealand



FUNDRAISING HIGHLIGHT:

18 Individuals and 5 teams signed up to our Step Up Challenge to inspire, empower and celebrate women during gynaecological cancer awareness month. Together they had fun being active, raising \$18,502 for ovarian cancer in the process.

Amanda, Carmen and Laura completed the Spring Challenge Adventure in honour of their friend Kate.

"Her positivity inspired us to challenge ourselves to travel a combined more than 1000 kms in training for, and competing in, the Spring Challenge Adventure Race"

MENTIONS IN NEW ZEALAND MEDIA

<https://www.nzdoctor.co.nz/article/ovarian-cancer-easy-miss-dont-let-lead-delays-diagnosis>

<https://www.stuff.co.nz/national/health/128876228/you-have-to-be-a-squeaky-wheel-doctor-tells-southland-women>

<https://www.odt.co.nz/lifestyle/magazine/souths-most-inspirational-part-five>

<https://www.tvnz.co.nz/one-news/new-zealand/help-stop-women-dying-ovarian-cancer-sufferer-calls-more-funding-treat-disease>

<https://focusmagazine.co.nz/three-women-cycle-run-and-walk-1000-kilometres-to-support-their-friend-and-raise-funds-for-ovarian-cancer-awareness/>

<https://www.odt.co.nz/regions/north-otago/cancer-message-gets-huge-billing>

<https://www.huttvalleydhb.org.nz/media-and-latest-news/latest-news/2021-09-22-mums-warning-look-out-for-signs-of-ovarian-cancer/>

<https://bpac.org.nz/bulletin/bestpractice/forty-four.aspx>

<https://www.audible.com/pd/Cure-Our-Ovarian-Cancer-with-Jane-Ludemann-Podcast/B09SY8CHH3>

<https://www.stuff.co.nz/national/health/125212178/woman-died-from-ovarian-cancer-after-being-told-she-likely-had-an-sti>

<https://www.newshub.co.nz/home/new-zealand/2021/07/cancer-patients-advocates-gobsmacked-pharmac-declining-funding-application-for-life-changing-drug.html>

<https://coastandcountrynews.co.nz/news/6724-rural-women-speak-up-about-silent-killer-cancer.html>

<https://www.odt.co.nz/news/dunedin/patients-lie-down-cause>

July 31st The Listener: Sure Signs: A Dunedin based charity dedicated to improving the detection and treatment of ovarian cancer

<https://www.newshub.co.nz/home/new-zealand/2021/07/cancer-patients-advocates-gobsmacked-pharmac-declining-funding-application-for-life-changing-drug.amp.html>

<https://sunlive.co.nz/news/274933-the-high-price-of-living-cancer.html>

<https://www.stuff.co.nz/national/health/127301383/cancer-patient-says-petition-for-education-shouldnt-be-fobbed-off>

STATEMENT OF SERVICE PERFORMANCE

WORLDWIDE (LOW-GRADE SEROUS OVARIAN CANCER)

HONOURING JESS'S CONTRIBUTION



Before cancer, Jess Becraft was a career-driven, world-traveling, Chicago-loving woman. In January 2018 during an unplanned C-section to deliver her beautiful daughter, it was discovered Jess had a rare form of stage 3C ovarian cancer, low-grade serous carcinoma (LGSC).

A chance encounter between Cure Our Ovarian Cancer founder Jane Ludemann and Jess in 2019 helped spark a desire to use her skills and strength as a marketer to drive efforts for low-grade serous cancer research in the United States.

Together with her friends Alex Feldt and Bailey Wolfe she launched STAAR Ovarian Cancer Foundation and worked with Cure Our Ovarian Cancer to raise funds for low-grade serous cancer research in America.

But her most important job was being a mom.



JESS BECRAFT PASSED AWAY
IN SEPTEMBER 2021 AT AGE 37



In the words of Jess's brother and STAAR Ovarian Cancer Board Member Nick:

My sister Jess was so much more than her cancer. She was an incredible leader. She was wildly successful in her career. She was an amazing mother, wife, daughter, sister, and friend. She was passionate about everything she put her time into.

I think towards the end she was identified so much by her cancer and I just want to remind people that she was more than just that. Her advocacy and hard work towards LGSC and the community she helped build is so important and is left in amazing hands with Nicole, Morgan, and the rest of those involved with STAAR.

Everyday I think about my sister and it gives me peace knowing how proud she is. I wish every day she was still here and would give the world to have her back with us, but I pray that because of what she helped create, one day there will be some other 4 year old daughter, or mother, or husband, or brother, who doesn't lose their loved one to this.

I am proud of my sister. There is no other way to say it.

- Nick Gilbertson



On Mother's Day in 2020 Jess wrote the following:

“When I imagined my life as a mom, it certainly never, ever looked like this. I thought I'd struggle most with balancing my career and wanting to be the best mom possible - the mom who'd see to it that my little girl grew up to be a smart, independent, strong woman. Though my desire to be the best mom possible still exists, now my days are full of wishing I could play more, wishing I felt better so that I could be like other moms, trying to still bond, have fun, and discipline, while also sometimes wondering how long I'll be here. Though I fully intend to beat the odds, I still want to make sure that Harper has the impact of a mom on her life, even if I do leave this earth before she truly remembers me.

From my very first Mother's Day to my very last, it'll be a tough day. It always includes wondering how many more of these I'll get and how hard this day will be for Harper when I'm gone. Mother's Day should be a day of complete celebration - a day of spending time with my people, getting flowers, and doing no chores. Instead, behind my smile are tears, just waiting to come out. Instead, it's hard to even want to be celebrated because it somehow makes me feel like a ticking time bomb.

So, I instead try to shift focus to my mom - the one who's been with me every step of the way, the one who moved in with my family to help with daily life, the one who's always there and always will be. Though, this day is hard for her too. Until I became a mom, I didn't fully understand how my mom felt about me... and for her, it's a day of pain too - she wants me to be ok, she wants my pain go to away, she wants to make it the best day ever for me, all the while wishing it was different, wishing we both didn't have this burden.



SUPPORT

- Connecting people: Our Facebook group the Low-Grade Serous Ovarian Cancer Peer Support Group, supported 97 people with low-grade serous carcinoma and 155 people through the Low Grade Serous Ovarian Cancer Support Group for Family/Careers/Friends.
- Informing choices: added four new articles on topics relevant to LGSC including managing cognitive side effects and an interview with UK researcher Professor Charlie Gourley.

RAISING AWARENESS OF LOW-GRADE SEROUS OVARIAN CANCER

- Cure Our Ovarian Cancer's World Ovarian Cancer Campaign appeared on over 350 billboards across the UK and in the US including Piccadilly Circus and New York Times Square with coverage in UK and Canadian media.
- Our social media posts on low-grade serous carcinoma and symptoms awareness in younger women reached 322,181 people on Facebook and 91,986 people on Instagram.



BILLBOARD CAMPAIGN TIMES SQUARE, NEW YORK

SPEAKING UP FOR RARE OVARIAN CANCERS AND VISITING OUR RESEARCHERS

In March 2022 Cure Our Ovarian Cancer Founder Jane Ludemann was invited to speak at a session on rare ovarian cancers at the Society of Gynecologic Oncology conference - one of the largest gatherings of gynaecological cancer specialists in the world.

One of her key messages was the importance of empowering people with rare ovarian and gynaecological cancers to access information relevant to their disease and connect with others sharing a lived experience.

"Don't Google", is an unhelpful statement that disempowers people from making informed decisions about their health. Instead people should be directed to sources of good information and patient groups. Jane provided tips to find these rare disease groups and information.


Jane also had the opportunity to participate in a gathering of low-grade serous cancer experts, discussing future research to improve treatments and care.

While Jane was in the United States she had the opportunity to connect with Nicole Andrews and Morgan Gaynor on the board of STAAR Ovarian cancer and discussed ways to further collaborate and build on each others success for the low-grade serous cancer community.

Nicole and Jane visited Dr KK Wong at his laboratory at The University of Texas MD Anderson Cancer Center. Cure Our Ovarian Cancer and STAAR Ovarian Cancer have supported two of their research projects. This valuable source of low-grade serous research is primarily supported by people with this disease and it was inspiring to hear of his laboratory's dedication and enthusiasm for low-grade serous cancer. Dr KK Wong, is one of just a few scientists investigating low-grade serous cancer in America, alongside his post-doctoral fellow Dr Oscar Ng and technician Yvonne Tsang so his lab is very precious!



JANE AT THE SOCIETY OF GYNECOLOGIC ONCOLOGY CONFERENCE



L TO R: JANE LUDEMANN, NICOLE ANDREWS, DR KK WONG, DR OSCAR NG, YVONNE TSANG

Jane also had the opportunity to visit the BC Cancer Foundation with Amy MacRae's parents - Betty and Kerry Ho. Amy passed away from low-grade serous cancer in 2020. Her family and friends have been tireless supporters of low-grade serous cancer research - raising over \$100,000 in Amy's name. As part of these efforts, Amy's life inspired the formation of The Amy Award (amyaward.com) an international writing competition that has resulted in the publication of a book with proceeds supporting research.

Dr Mark Carey's laboratory based at BC Cancer in Vancouver is the largest research laboratory focused on low-grade serous cancer in the world and their cancer models are used by researchers around the world. It was inspiring to see their commitment to low-grade serous cancer and the difference the funds we raise make to their ability to progress survival.

Jane paid for her own travel and expenses.



CAREY LAB WITH JANE (2ND L) AND BETTY AND KERRY HO (FAR R)



AMY'S FATHER KERRY PICTURED WITH THE AMY AWARD BOOK

RESEARCH

RAISING FUNDS FOR LOW-GRADE SEROUS RESEARCH:



HOW RESEARCH FUNDS ARE BEING USED:

AUSTRALIA

Our Australian charity partner ANZGOG is currently in negotiations for funding and development of the first specific low-grade serous carcinoma clinical trial to be initiated in Australasia.

The Covid-19 epidemic contributed to significant delays, and the Phase I trial to determine the optimal dosage for the Phase II trial is still on-going.

The trial, called ALEGRO is a phase II trial and will investigate two new combination drugs. The drugs belong to a class of treatments called MEK inhibitors and BRAF inhibitors.

CANADA

Dr. Carey's laboratory continues to work on behalf of patients with Low-grade Serous Ovarian Cancer supported by Cure our Ovarian Cancer and the BC Cancer Foundation. The lab continues their work to develop research models for drug testing. Last year they established 3 new cell line models and these are being tested to see if they will grow in mice. They are also doing important work to establish patient-derived xenografts (patient low-grade cancers growing in mice). Several xenograft models have been established with the support of Cure our Ovarian Cancer and Ovarian Cancer Canada.

Cell lines from the Carey Laboratory are being used for two important drug screens, one in Australia under the direction of Drs. Dane Cheasley and Kathleen Pishas, and the other in Edinburgh under the direction of Dr. Charlie Gourley. Ideally, the drug screen candidates identified in the screens are best evaluated in the xenograft models in preparation for patient trials. These studies will hopefully lead to better treatments.

The Carey laboratory is also investigating how hormone therapies work in Low-grade Serous Cancers (LGSOC) by testing these treatments in mice models and then evaluating the molecular changes we identify in patient samples. With the support of Cure Our Ovarian Cancer, the Carey Lab funds one the the technicians working on this important project. We need to better understand how anti-hormone therapies work as treatment for LGSOC.

Work continues to establish a National database for patients with LGSOC and through this, establish a network for patient clinical trials. They have just developed a National agreement for data collection and 6 centers across the country are joining. The Carey Lab is also a member of the International Consortium for Low-grade Serous Ovarian Cancer, a group sponsored by the Ludemann family, dedicated to improving outcomes for patients diagnosed with this disease.

NEW ZEALAND

Fund's raised for Graci contributed to Dr Chitcholtan's grant discussed on page 19.

UNITED KINGDOM

All funds raised for Low Grade Serous Ovarian Cancer (LGSOC) research in the UK are being directed to the Edinburgh Cancer Research Centre, part of the University of Edinburgh, to support Professor Charlie Gourley and his team who are focussed on understanding the genetic and genomic origins of low-grade serous ovarian cancer, and, how this information can be used to better detect and treat this disease.

The funds raised to date are being used to fund a scientist (Rosie Matthews) to make better laboratory models of low grade serous ovarian cancer in the hope that one day we may be able to do this for all patients and screen their tumours in the lab for the therapies most likely to work for them. Some of the funds are also being used in the lab to work out what new drugs might work best at killing low grade serous ovarian cancer cells when given in combination with trametinib.

UNITED STATES

Cure Our Ovarian Cancer contributed to a research project funded by STAAR Ovarian Cancer awarded to Dr Wong at The University of Texas MD Anderson Cancer Center. The project - Biomarkers of Sensitivity to Aromotase Inhibitors in Women with Recurrent Low-Grade serous Ovarian/Peritoneal Cancer seeks to determine if biomarkers can identify how aromatase inhibitors influence the clinical outcomes of patients with low-grade serous ovarian cancer.



"I remember diagnosis day very well. The confirmation it was cancer was not a surprise as the oncology team had already said they were 99% certain it was cancer. The surprises came when I was told it was a rare type of ovarian cancer, that there wasn't an effective treatment for it and that there wasn't really any research for it as it was so rare that drug companies were less interested in it.

Seven years later and in that time I feel like I've seen real change. Whilst we haven't got a magic pill that will work for all of us, what we do have is hope and that is priceless. So thank you for hope for those of us living with low grade ovarian and primary peritoneal cancer and for enabling us to pass that hope on to everyone who is being diagnosed every day across the world."

- Kathryn, low-grade serous ovarian cancer

MENTIONS IN THE INTERNATIONAL MEDIA

<https://www.independent.co.uk/independentpremium/lifestyle/ovarian-cancer-day-piccadilly-circus-b1843931.html>

<https://oceanoutdoor.com/ocean-news/news/women-with-deadly-cancer-organise-piccadilly-lights-and-times-square-billboard-campaign-to-raise-awareness/>

<https://podcasts.apple.com/gb/podcast/ep-17-hannah-campaigner-for-raising-awareness/id1544135464?i=1000552568451>

<https://www.healthdigest.com/260999/if-youre-bloated-all-the-time-this-is-probably-why/>

<https://sg.news.yahoo.com/belly-button-saved-life-130000563.html>

<https://www.surreynowleader.com/news/surrey-woman-a-face-of-world-ovarian-cancer-day-campaign-in-london-new-york/>

<https://bc.ctvnews.ca/video?clipId=2198294&jwsourc=em>

STATEMENT OF FINANCIAL PERFORMANCE

CURE OUR OVARIAN CANCER CHARITABLE TRUST
As at 31 March 2022

Revenue	Notes	2022	2021
Donations, fundraising and other similar revenue	1	110,313	172,423
Total Revenue		110,313	172,423

Expenses	Notes	2022	2021
Expenses related to public fundraising	2	2,867	4,587
Costs related to providing goods or services	2	5,693	13,637
Grants and donations made	2	62,007	67,024
Total Expenses		70,566	85,247
Surplus/(Deficit) for the Year		39,746	87,176

This statement has been prepared without conducting an audit or review engagement, and should be read in conjunction with the accounting policies and notes to the Performance Report

STATEMENT OF FINANCIAL POSITION

CURE OUR OVARIAN CANCER CHARITABLE TRUST
As at 31 March 2022

Assets	Notes	2022	2021
Current Assets			
Bank accounts and cash	3	291,731	225,771
Debtors and prepayments	3	0	6,435
Total Current Assets		291,732	232,206
Total Assets		291,732	232,206

Liabilities	Notes	2022	2021
Current Liabilities			
Creditors and accrued expenses	4	695	5,916
Grants in Advance	4	25,000	0
Total Current Liabilities		25,695	5,916
Total liabilities		25,695	5,916
Total Assets less Total Liabilities (Net Assets)		266,036	226,290

Accumulated Funds	Notes	2022	2021
Accumulated surpluses or (deficits)	5	266,036	226,290
Total accumulated Funds		266,036	226,290

This statement has been prepared without conducting an audit or review engagement, and should be read in conjunction with the accounting policies and notes to the Performance Report

STATEMENT OF CASH FLOWS

CURE OUR OVARIAN CANCER CHARITABLE TRUST

As at 31 March 2022

Cash Flows from Operating Activities	2022	2021
Donations, fundraising and other similar receipts	116,099	170,624
Cash receipts from other operating activities	25,000	0
Payments to suppliers	(13,132)	(15,557)
Donations or grants paid	(62,007)	(67,024)
Total Cash Flows from Operating Activities	65,961	88,043
Net Increase/(Decrease) in Cash	65,961	88,043

Bank Accounts and Cash	2022	2021
Opening Cash	(225,771)	(137,728)
Closing Cash	(291,731)	(225,771)
Net change in cash for period	(65,961)	(88,043)

This statement has been prepared without conducting an audit or review engagement, and should be read in conjunction with the accounting policies and notes to the Performance Report

STATEMENT OF ACCOUNTING POLICIES

HOW DID WE DO OUR ACCOUNTING?

BASIS OF PREPARATION

The entity has elected to apply PBE SFR-A (NFP) Public Benefit Entity Simple Format Reporting - Accrual (Not-For-Profit) on the basis that it does not have public accountability and has total annual expenses equal to or less than \$2,000,000. All transactions in the Performance Report are reported using the accrual basis of accounting. The Performance Report is prepared under the assumption that the entity will continue to operate in the foreseeable future.

The Performance Report is presented in New Zealand dollars.

GOODS AND SERVICES TAX (GST)

The entity is not registered for GST. Therefore all amounts are stated inclusive of GST (if any).

INCOME TAX

Cure Our Ovarian Cancer Charitable Trust is wholly exempt from New Zealand income tax having fully complied with all statutory conditions for these exemptions.

BANK ACCOUNTS AND CASH

Bank accounts and cash in the Statement of Cash Flows comprise cash balances and bank balances (including short term deposits) with original maturities of 90 days or less.

CHANGES IN ACCOUNTING POLICIES

There have been no changes in accounting policies. Policies have been applied on a consistent basis with those of the previous reporting period.

NOTES TO THE PERFORMANCE REPORT

1. Analysis of Revenue	2022	2021
Donations, fundraising and other similar revenue		
Donations	105,851	172,423
Grants	4,461	0
Total Donations, fundraising and other similar revenue	110,313	172,423
Breakdown of Cure Our Ovarian Cancer Net Donations collected for research by region		
New Zealand	96,520	65,105
Australia	0	136
Canada	3,308	27,413
Europe	0	105
UK	0	364
USA	552	65,399
Total Breakdown of Cure Our Ovarian Cancer Net Donations collected for research by region	100,380	158,522
2. Analysis of Expenses		
Expenses related to public fundraising		
Promotion and Marketing	1,424	1,873
Website	1,443	2,714
Total Expenses related to public fundraising	2,867	4,587
Costs related to providing goods or services		
Administration and overhead costs	1,851	717
Advocacy & Awareness	1,400	6,940
Financial Reporting Costs	1,776	1,301
Payment Processing Fees	666	4,678
Total Costs related to providing goods or services	5,693	13,637

2. Analysis of Expenses continued.	2022	2021
Grants and donations made		
Donations to Charity Partners	62,007	67,024
Total Grants and Donations made	62,007	67,024
Recipients of Donations to Charity Partners		
GRACI	32,900	0
BC Cancer Foundation	0	29,326
The University of Texas MD Anderson Cancer Center	0	33,682
University of Edinburgh	29,107	4,016
Total Recipients of Donations to Charity Partners	62,007	67,024
3. Analysis of Assets		
Bank Accounts and Cash		
Australia	126	126
Canada	3,206	0
Europe	178	178
Expenses Account	1,388	938
NZ Purposes Trust	283,889	193,153
US	2,945	31,376
Total Bank Accounts and Cash	291,731	225,771
Debtors and prepayments		
Donations receivable	0	6,435
Total Debtors and prepayments	0	6,435
4. Analysis of Liabilities		
Creditors and accrued expenses		
Creditors and accrued expenses	695	5,916
Total Creditors and accrued expenses	695	5,916
Unused donations and grants with conditions		
Grants In Advance - Lottery Community	25,000	0
Total unused donations and grants with conditions	25,000	0

5. Accumulated Funds	2022	2021
Accumulated Funds		
Opening Balance	226,290	139,114
Accumulated surpluses or (deficits)		
Current year earnings	39,746	87,176
Total Accumulated surpluses or (deficits)	39,746	87,176
Total Accumulated Funds	266,036	226,290
Total Accumulated Funds	266,036	226,290

As per last year, \$150,000 of accumulated funds continue to be held with the intention of bringing a low-grade serous ovarian cancer trial to NZ. The trial remains in development.

6. Commitments

There are no commitments as at 31 March 2022 (Last year - \$10,000 GRACI).

7. Contingent Liabilities and Guarantees

There are no contingent liabilities or guarantees as at 31 March 2022 (Last year - nil).

8. Related Parties	2022	2021
Donations		
Trustees and close family members - Donations	5,471	23,901
Total Donations	5,471	23,901
Expenses		
Trustees - Expenses paid on behalf of the charity	2,233	5,901
Total Expenses	2,233	5,901


The Trustees provide 40-60 hours per week of time and skills to the oversight and operation of the Trust at no charge.

9. Events After the Balance Date

There were no events that have occurred after the balance date that would have a material impact on the Performance Report (Last year - nil).



MIRACLE MARSH



SHARON



MANDA



BROOKE



MARIE



JENNIFER



DIANE



COURTNEY



CHASITY



WENDY



REBECCA




CLARE



KIM



CASSONDRA




DOT



LAURA



CECILY



SYLVIA



EMILY



cureourovariancancer.org